Identifíquese
¿Aún no es suscriptor de la revista?
Comprar el acceso al artículo
Comprando el artículo el pdf del mismo podrá ser descargado
Teléfono para incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
Bibliografía
[1]
G. Scott, T.J. Coleman.
Leptospirosis.
Manson's tropical diseases, 21th, Saunders, pp. 1165-1171
[2]
D. Stone.
Zoonosis.
Infectious diseases, 3a ed., Lippincott Williams and Wilkins, pp. 1423-1534
[3]
P. Vijayachari, A.P. Sugunan, A.N. Shriram.
Leptospirosis: an emerging global public health problema.
J Biosci, (2008), 33 pp. 557-569
[4]
T.J. John.
The prevention and control of human leptospirosis.
J Postgrad Med, (2005), 51 pp. 205-209
[5]
R. Plank, D. Dean.
Overview of the epidemiology, microbiology, and pathogenesis of Leptospira spp. in humans.
Microbes Infect, (2000), pp. 1265-1276
[6]
J.W. Tappero, D.A. Ashford, B.A. Perkins.
Leptospirosis.
Principles and practice of infectious diseases, 5th ed., Churchill Livingstone, pp. 2495-2501
[7]
G. Pappas, P. Papadimitriou, V. Siozopoulou, L. Christou, N. Akritidis.
The globalization of leptospirosis: worldwide incidence trends.
Int J Infect Dis, (2008), 12 pp. 351-357
[8]
A. Pavli, H.C. Maltezou.
Travel-acquired leptospirosis.
J Travel Med, (2008), 15 pp. 447-453
[9]
J.F. Wagenaar, M.G. Goris, M.S. Sakundarno, M.H. Gasem, A.T. Mairuhu, M.D. de Kruif, et al.
What role do coagulation disorders play in the pathogenesis of leptospirosis?.
Trop Med Int Health, (2007), 12 pp. 111-122
[10]
R.U. Palaniappan, S. Ramanujam, Y.F. Chang.
Curr Opin Infect Dis.
Leptospirosis: pathogenesis, immunity, and diagnosis, (2007), 20 pp. 284-292
[11]
A.J. McBride, D.A. Athanazio, M.G. Reis, A.I. Ko.
Leptospirosis.
Curr Opin Infect Dis, (2005), 18 pp. 376-386
[12]
M.E. Zunino, P.R. Pizarro.
Leptospirosis: a literature review.
Rev Chilena Infectol, (2007), 24 pp. 220-226
[13]
T.B. Cerqueira, D.A. Athanazio, A.S. Spichler, A.C. Seguro.
Renal involvement in leptospirosis–new insights into pathophysiology and treatment.
Braz J Infect Dis, (2008), 12 pp. 248-252
[14]
R.C. Abdulkader, M.V. Silva.
The kidney in leptospirosis.
Pediatr Nephrol, (2008), 23 pp. 2111
[15]
S. Visith, P. Kearkiat.
Nephropathy in leptospirosis.
J Postgrad Med, (2005), 51 pp. 184-188
[16]
M. Dolhnikoff, T. Mauad, E.P. Bethlem, C.R. Carvalho.
Pathology and pathophysiology of pulmonary manifestations in leptospirosis.
Braz J Infect Dis, (2007), 11 pp. 142-148
[17]
M. Dolhnikoff, T. Mauad, E.P. Bethlem, C.R. Carvalho.
Leptospiral pneumonias.
Curr Opin Pulm Med, (2007), 13 pp. 230-235
[18]
B. Dursun, F. Bostan, M. Artac, H.I. Varan, G. Suleymanlar.
Severe pulmonary haemorrhage accompanying hepatorenal failure in fulminant leptospirosis.
Int J Clin Pract, (2007), 61 pp. 164-167
[19]
S.R. Rathinam.
Ocular manifestations of leptospirosis.
J Postgrad Med, (2005), 51 pp. 189-194
[20]
A.M. Bal.
Unusual clinical manifestations of leptospirosis.
J Postgrad Med, (2005), 51 pp. 179-183
[21]
A. Stefos, S.P. Georgiadou, C. Gioti, A. Loukopoulos, M. Ioannou, S. Pournaras, et al.
Leptospirosis and pancytopenia: two case reports and review of the literature.
J Infect, (2005), 51 pp. e277-e280
[22]
S.N. Ahmad, S. Shah, F.M. Ahmad.
Laboratory diagnosis of leptospirosis.
J Postgrad Med, (2005), 51 pp. 195-200
[23]
G. Pappas, A. Cascio.
Optimal treatment of leptospirosis: queries and projections.
Int J Antimicrob Agents, (2006), 28 pp. 491-496
[24]
M.E. Griffith, D.R. Hospenthal, C.K. Murray.
Antimicrobial therapy of leptospirosis.
Curr Opin Infect Dis, (2006), 19 pp. 533-537
[25]
J. Mensa, J.M. Gatell, J.E. García-Sánchez, E. Letang, E. López-Suñé.
Guía de terapéutica antimicrobiana.
19a ed., Ediciones Masson, (2009),
[26]
L. Raptis, G. Pappas, N. Akritidis.
Use of ceftriaxone in patients with severe leptospirosis.
Int J Antimicrob Agents, (2006), 28 pp. 259-261
[27]
Y. Suputtamongkol, K. Niwattayakul, C. Suttinont, K. Losuwanaluk, R. Limpaiboon, W. Chierakul, et al.
An open, randomized, controlled trial of penicillin, doxycycline, and cefotaxime for patients with severe leptospirosis.
Clin Infect Dis, (2004), 39 pp. 1417-1424
[28]
C. Emmanouilides, O. Kohn, R. Garibaldi.
Leptospirosis complicated by a Jarisch-Herxheimer reaction and adult respiratory distress syndrome: case report.
Clin Infect Dis, (1994), 18 pp. 1004-1006
[29]
Y. Kobayashi.
Human leptospirosis: management and prognosis.
J Postgrad Med, (2005), 51 pp. 201-204
[30]
J. Chin.
Control of communicable diseases manual.
17a ed., American Public Health Association, (2000),
[31]
E.R. Cachay, J.M. Vinetz.
A global research agenda for leptospirosis.
J Postgrad Med, (2005), 51 pp. 174-178
[32]
N. Koizumi, H. Watanabe.
Leptospirosis vaccines: past, present, and future.
J Postgrad Med, (2005), 51 pp. 210-214
[33]
V. Thongboonkerd.
Proteomics in leptospirosis research: towards molecular diagnostics and vaccine development.
Expert Rev Mol Diagn, (2008), 8 pp. 53-61
Copyright ©
2010. Elsevier España, S.L.. Todos los derechos reservados
